Napren-E (Naproxen)

Naproxen, the active ingredient in Napren‑E, is a nonsteroidal anti‑inflammatory drug presented as an oral tablet for oral use. It is used to relieve mild to moderate pain, reduce inflammation in conditions such as arthritis, treat dysmenorrhea and lower fever.

GNH USA supplies Napren‑E as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Naproxen acts on inflammatory pathways and is indicated for several common pain‑related conditions.

- Mild to moderate pain: provides analgesic relief for headaches, dental pain, and musculoskeletal aches. - Osteoarthritis and rheumatoid arthritis: reduces joint inflammation and improves mobility. - Dysmenorrhea: alleviates menstrual cramps and associated discomfort. - Fever: lowers elevated body temperature in acute febrile states.

Naproxen may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal upset (nausea, dyspepsia) - Abdominal pain - Heartburn - Dizziness - Headache - Mild rash

Serious or Rare Side Effects: - Gastrointestinal bleeding or ulcer perforation - Renal impairment or failure - Hepatic dysfunction - Severe skin reactions such as Stevens‑Johnson syndrome - Cardiovascular events including thrombotic complications

When prescribing naproxen, consider the following precautions to minimize risk.

- Assess gastrointestinal risk: avoid in patients with active ulcers or a history of GI bleeding. - Monitor renal function: use cautiously in those with impaired kidney function. - Evaluate cardiovascular status: consider risk in patients with heart disease or hypertension. - Review concomitant medications: avoid combined use with other NSAIDs or anticoagulants unless necessary. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Naproxen can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (warfarin, DOACs): increased bleeding risk. - Selective COX‑2 inhibitors (celecoxib): additive gastrointestinal toxicity. - High‑dose aspirin: heightened renal and GI adverse effects. - Lithium: naproxen may raise lithium serum levels. - Methotrexate: reduced clearance leading to toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors/ARBs: may diminish antihypertensive effect and affect renal function. - Diuretics: increased risk of renal impairment. - SSRIs/SNRIs: heightened bleeding tendency. - Corticosteroids: additive gastrointestinal ulcer risk. - Beta‑blockers: possible reduction in antihypertensive response.